Vancomycin Containing PLLA/β-TCP Controls MRSA In Vitro

Kankilic, Berna; Bayramlı, Erdal; Kılıç, Emine; Dagdeviren, Sezin; Korkusuz, Feza

doi:10.1007/s11999-011-2082-9

Cited by 24 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is the phase when the drug molecules at the surface or near the surface are released 27 , 31 . Although initial burst, which is typical for drug releasing polymeric materials, has been claimed as unwanted phenomenon, 28 , 29 it may be beneficial when the target is to destroy remaining bacteria after the surgical debridement of infected tissue. If the burst is moderate, it may help to achieve the required antibiotic concentration in the tissue and eradicate bacteria or to prevent the attachment of bacteria to the operated bone or implant 10 , 30 …”

Section: Resultsmentioning

confidence: 99%

An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis

et al. 2013

View full text Add to dashboard Cite

Osteomyelitis is a bacterial disease that can become chronic, and treatment often includes a surgical operation to remove infected bone. The aim of this study was to develop and investigate in vitro bone filling composite materials that release ciprofloxacin to kill any remaining bacteria and contain bioceramic to help the bone to heal. Three composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin were compounded using twin-screw extrusion and sterilized by gamma irradiation. Drug release and degradation of the composites were investigated in vitro for 52 weeks. The composite with 50 wt% of β-TCP had the most promising ciprofloxacin release profile. The ceramic component accelerated the drug release that occurred in three phases obeying first-order kinetics. Inhibition zone testing using bioluminescence showed that the released ciprofloxacin had effect in eradicating a common osteomyelitis causing bacteria Pseudomonas aeruginosa. During the in vitro degradation test series, molar weight of the polymer matrix of the composites decreased rapidly. Additionally, 1H-NMR analysis showed that the polymer had blocky structure and the comonomer ratio changed during hydrolysis. The tested composites showed great potential to be developed into bone filler materials for the treatment of osteomyelitis or other bone related infections.

show abstract

Section: Resultsmentioning

confidence: 99%

An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Composites were developed and characterized as previously described [ 17 ]. Briefly, 8% vancomycin solution was prepared with 920 mg deionized water.…”

Section: Methodsmentioning

confidence: 99%

“…Although various degradable polymers [ 12 , 13 ] and β-TCP [ 14 ] were used to release antibiotics, in vivo evaluation of these systems was rarely [ 15 , 16 ] undertaken. A vancomycin-containing poly-l-lactic acid/β-tricalcium phosphate (V-PLLA/β-TCP) composite was recently developed and characterized for this reason [ 17 ]. PLLA slowed vancomycin release and β-TCP aided mesenchymal stem and Saos-2 bone cells attachment, proliferation, and differentiation in vitro [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…A vancomycin-containing poly-l-lactic acid/β-tricalcium phosphate (V-PLLA/β-TCP) composite was recently developed and characterized for this reason [ 17 ]. PLLA slowed vancomycin release and β-TCP aided mesenchymal stem and Saos-2 bone cells attachment, proliferation, and differentiation in vitro [ 17 ]. This composite was further dip coated (C) with PLLA and 63.1% and 91.9% of the vancomycin released on days 1 and 42, respectively.…”

Section: Introductionmentioning

confidence: 99%

“…This composite was further dip coated (C) with PLLA and 63.1% and 91.9% of the vancomycin released on days 1 and 42, respectively. CV- and V-PLLA/β-TCP composites furthermore generated the extracellular bone matrix and attained mineralization that may point out tissue regeneration [ 17 ]. In this study, we asked whether CV- and V-PLLA/β-TCP composites controlled experimental IRO and promoted bone healing in vivo .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vancomycin containing PLLA/β-TCP controls experimental osteomyelitis in vivo

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundImplant-related osteomyelitis (IRO) is recently controlled with local antibiotic delivery systems to overcome conventional therapy disadvantages. In vivo evaluation of such systems is however too little.Questions/purposesWe asked whether vancomycin (V)-containing poly-l-lactic acid/β-tricalcium phosphate (PLLA/β-TCP) composites control experimental IRO and promote bone healing in vivo.MethodsFifty-six rats were distributed to five groups in this longitudinal controlled study. Experimental IRO was established at tibiae by injecting methicillin-resistant Staphylococcus aureus (MRSA) suspensions with titanium particles in 32 rats. Vancomycin-free PLLA/β-TCP composites were implanted into the normal and infected tibiae, whereas V-PLLA/β-TCP composites and coated (C)-V-PLLA/β-TCP composites were implanted into IRO sites. Sham-operated tibiae established the control group. Radiological and histological scores were quantified with microbiological findings on weeks 1 and 6.ResultsIRO is resolved in the CV- and the V-PLLA/β-TCP groups but not in the PLLA/β-TCP group. MRSA was not isolated in the CV- and the V-PLLA/β-TCP groups at all times whereas the bacteria were present in the PLLA/β-TCP group. Radiological signs secondary to infection are improved from 10.9 ± 0.9 to 3.0 ± 0.3 in the V-PLLA/β-TCP group but remained constant in the PLLA/β-TCP group. Histology scores are improved from 24.7 ± 6.5 to 17.6 ± 4.8 and from 27.6 ± 7.9 to 32.4 ± 8.9 in the CV-PLLA/β-TCP and the V-PLLA/β-TCP groups, respectively. New bone was formed in all the PLLA/β-TCP group at weeks 1 and 6.ConclusionsCV- and V-PLLA/β-TCP composites controlled experimental IRO and promoted bone healing.Clinical relevanceCV- and V-PLLA/β-TCP composites have the potential of controlling experimental IRO and promoting bone healing.

show abstract

Poly (ε‐caprolactone) coating delays vancomycin delivery from porous chitosan/β‐tricalcium phosphate composites

et al. 2012

View full text Add to dashboard Cite

The orthopedic infection, such as osteomyelitis, especially those caused by Methicillin-resistant Staphylococcus aureus (MRSA), remains a major complication of open fractures. Local vancomycin delivery is considered to provide better methods when avascular zones prevent the delivery of drugs from conventional routes of administration. Chitosan (CS) delivery system has been developed with the disadvantages, such as mechanically weakness, lacking osteoconductivity, and the initial burst of antibiotics into the environment. The aim of this study was to confirm that the prepared CS/β-tricalcium phosphate (β-TCP) composites coated with poly (ε-caprolactone) (PCL), similar to natural bone in components, had a three-dimensional porous structure and could be used as drug carriers to deliver vancomycin in a sustained and controlled manner effectively for 6 weeks at levels to inhibit MRSA proliferation. We prepared porous CS/β-TCP composites by incorporating β-TCP into the system, and coated the composites with PCL of three different concentrations. The morphological structure of composites, including pore size and porosity, was examined. The result showed that CS/β-TCP coated with 2.5w/v% PCL solution had the best coating effect and it retarded the release of vancomycin in a near zero-order mechanism from 0 to 14 days. The drug delivery was significantly delayed after coated with 2.5w/v% PCL. The quantitative release of vancomycin was extended to 42 days. Therefore PCL coating could be used to retard the release of vancomycin from CS/β-TCP composites in a sustained and controlled manner. Porous CS/β-TCP coated with PCL might be one of the candidate vancomycin carriers for treating MRSA-related osteomyelitis.

show abstract

Vancomycin Containing PLLA/β-TCP Controls MRSA In Vitro

Abstract: Vancomycin-containing PLLA/β-TCP composites may be useful for controlling MRSA but will require in vivo confirmation.

Cited by 24 publications

References 44 publications

An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis

An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis

Vancomycin containing PLLA/β-TCP controls experimental osteomyelitis in vivo

Poly (ε‐caprolactone) coating delays vancomycin delivery from porous chitosan/β‐tricalcium phosphate composites

Contact Info

Product

Resources

About